Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on adolescent vaping

LIVE: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?
ADVANCED SEARCH
Log in
Top
Heart and Vessels

28-09-2024 | Angiography | Original Article

High plasma levels of fortilin are associated with cardiovascular events in patients undergoing coronary angiography

Authors: Masayuki Aoyama, Yoshimi Kishimoto, Emi Saita, Reiko Ohmori, Masato Nakamura, Kazuo Kondo, Yukihiko Momiyama

Published in: Heart and Vessels

Login to get access

Abstract

Excessive apoptosis and its insufficient clearance is characteristic of atherosclerotic plaques. Fortilin has potent antiapoptotic property and is abundantly expressed in atherosclerotic plaques. Fortilin-deficient mice had less atherosclerosis with more macrophage apoptosis. Recently, we reported that plasma fortilin levels were high in patients with coronary artery disease (CAD). However, its prognostic value has not been elucidated. We investigated plasma fortilin levels and major adverse cardiovascular events (MACE) in 404 patients (mean age 68 ± 12 years; 276 males) undergoing coronary angiography for suspected CAD. MACE was defined as cardiovascular death, myocardial infarction, unstable angina, heart failure, stroke, or coronary revascularization. Of the 404 patients, 218 (54%) had CAD. Plasma fortilin levels were higher in patients with CAD than without CAD (median 74.9 vs. 70.9 pg/mL, p < 0.05). During a mean follow-up of 5.7 ± 4.2 years, MACE was observed in 59 (15%) patients. Notably, patients with MACE had higher fortilin levels (median 83.0 vs. 71.4 pg/mL) and more often had fortilin level > 80.0 pg/mL (54% vs. 36%) than those without MACE (p < 0.025). A Kaplan-Meier analysis showed lower event-free survival in patients with fortilin > 80.0 pg/mL than in those with ≤ 80.0 pg/mL (p < 0.001). In multivariate Cox proportional hazards analysis, fortilin level (> 80.0 pg/mL) was an independent predictor of MACE (hazard ratio: 2.29, 95%CI: 1.36–3.85, p < 0.002). Among the 218 patients with CAD, fortilin level was also a significant predictor of MACE (hazard ratio: 2.48; 95%CI: 1.34–4.61, p < 0.005). Thus, high plasma fortilin levels were found to be associated with cardiovascular events in patients with CAD as well as those undergoing coronary angiography.
Literature
1.
2.
Sinthujaroen P, Wanachottrakul N, Pinkaew D, Petersen JR, Phongdara A, Sheffield-Moore M, Fujise K (2014) Elevation of serum fortilin levels is specific for apoptosis and signifies cell death in vivo. BBA Clin 2:103–111CrossRefPubMedPubMedCentral
3.
Pinkaew D, Le RJ, Chen Y, Eltorky M, Teng BB, Fujise K (2013) Fortilin reduces apoptosis in macrophages and promotes atherosclerosis. Am J Physiol Heart Circ Physiol 305:H1519–1529CrossRefPubMedPubMedCentral
4.
Kim JE, Koo KH, Kim YH, Sohn J, Park YG (2008) Identification of potential lung cancer biomarkers using an in vitro cacinogenesis model. Exp Mol Med 40:709–720CrossRefPubMedPubMedCentral
5.
Graidist P, Yazawa M, Tonganunt M, Nakatomi A, Lin CC, Chang JY, Phongdara A, Fujise K (2007) Fortilin binds Ca2+ and blocks Ca2+-dependent apoptosis in vivo. Biochem J 408:181–191CrossRefPubMedPubMedCentral
6.
Lucibello M, Gambacurta A, Zonfrillo M, Pierimarchi P, Serafino A, Rasi G, Rubartelli A, Garaci E (2011) TCTP is a critical survival factor that protects cancer cells from oxidative stress-induced cell-death. Exp Cell Res 317:2479–2489CrossRefPubMed
7.
Bommer UA, Vine KL, Puri P, Engel M, Belfiore L, Fildes K, Batterham M, Lochhead A, Aghmesheh M (2017) Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin. Cell Commun Signal 15:9CrossRefPubMedPubMedCentral
8.
Xiao B, Chen D, Luo S, Hao W, Jing F, Liu T, Wang S, Geng Y, Li L, Xu W, Zhang Y, Liao X, Zuo D, Wu Y, Li M, Ma Q (2016) Extracellular translationally controlled tumor protein promotes colorectal cancer invasion and metastasis through Cdc42/JNK/ MMP9 signaling. Oncotarget 7:50057–50073CrossRefPubMedPubMedCentral
9.
Rho SB, Lee JH, Park MS, Byun HJ, Kang S, Seo SS, Kim JY, Park SY (2011) Anti-apoptotic protein TCTP controls the stability of tumor suppressor p53. FEBS Lett 585:29–35CrossRefPubMed
10.
Ferrer E, Dunmore BJ, Hassan D, Ormiston ML, Moore S, Deighton J, Long L, Yang XD, Stewart DJ, Morrell NW (2018) A potential role for exosomal translationally controlled tumor protein export in vascular remodeling in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 59:467–478CrossRefPubMedPubMedCentral
11.
12.
Nagano-Ito M, Ichikawa S (2012) Biological effects of mammalian translationally controlled tumor protein (TCTP) on cell death, proliferation, and tumorigenesis. Biochem Res Int 2012:204960CrossRefPubMedPubMedCentral
13.
14.
15.
Kattoor AJ, Pothineni NVK, Palagiri D, Mehta JL (2017) Oxidative stress in atherosclerosis. Curr Atheroscler Rep 19:42CrossRefPubMed
16.
Steven S, Frenis K, Oelze M, Kalinovic S, Kuntic M, Jimenez MT, Vujacic-Mirski K, Helmstädter J, Kröller-Schön S, Münzel T, Daiber A (2019) Vascular inflammation and oxidative stress: major triggers for cardiovascular disease. Oxid Med Cell Longev 2019(1):7092151PubMedPubMedCentral
17.
Dong Y, Chen H, Gao J, Liu Y, Li J, Wang J (2019) Molecular machinery and interplay of apoptosis and autophagy in coronary heart disease. J Mol Cell Cardiol 136:27–41CrossRefPubMed
18.
Van Vré EA, Ait-Oufella H, Tedgui A, Mallat Z (2012) Apoptotic cell death and efferocytosis in atherosclerosis. Arterioscler Thromb Vasc Biol 32:887–893CrossRefPubMed
19.
Gautier EL, Huby T, Witztum JL, Ouzilleau B, Miller ER, Saint-Charles F, Aucouturier P, Chapman MJ, Lesnik P (2009) Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage. Circulation 119:1795–1804CrossRefPubMed
20.
Tulis DA, Mnjoyan ZH, Schiesser RL, Shelat HS, Evans AJ, Zoldhelyi P, Fujise K (2003) Adenoviral gene transfer of fortilin attenuates neointima formation through suppression of vascular smooth muscle cell proliferation and migration. Circulation 107:98–105CrossRefPubMed
21.
Cho Y, Maeng J, Ryu J, Shin H, Kim M, Oh GT, Lee MY, Lee K (2012) Hypertension resulting from overexpression of translationally controlled tumor protein increases the severity of atherosclerosis in apolipoprotein E knock-out mice. Transgenic Res 21:1245–1254CrossRefPubMed
22.
Kim MJ, Kwon JS, Suh SH, Suh JK, Jung J, Lee SN, Kim YH, Cho MC, Oh GT, Lee K (2008) Transgenic overexpression of translationally controlled tumor protein induces systemic hypertension via repression of Na+,K+-ATPase. J Mol Cell Cardiol 44:151–159CrossRefPubMed
23.
Aoyama M, Kishimoto Y, Saita E, Ohmori R, Tanimoto K, Nakamura M, Kondo K, Momiyama Y (2022) High plasma levels of fortilin in patients with coronary artery disease. Int J Mol Sci 23:8923CrossRefPubMedPubMedCentral
24.
Hamm CW, Braunwald E (2000) A classification of unstable angina revisited. Circulation 102:118–122CrossRefPubMed
25.
Chunhacha P, Pinkaew D, Sinthujaroen P, Bowles DE, Fujis K (2021) Fortilin inhibits p53, halts cardiomyocyte apoptosis, and protects the heart against heart failure. Cell Death Discov 7:310CrossRefPubMedPubMedCentral
26.
Saita E, Kishimoto Y, Aoyama M, Ohmori R, Kondo K, Momiyama Y (2023) Low plasma levels of soluble endoglin and cardiovascular events in patients undergoing coronary angiography. Biomedicines 11:2975CrossRefPubMedPubMedCentral
27.
Akobeng AK (2007) Understanding diagnostic tests 3: receiver operating characteristic curves. Acta Paediatr 96:644–647CrossRefPubMed
28.
Arima H, Kubo M, Yonemoto K, Doi Y, Ninomiya T, Tanizaki Y, Hata J, Matsumura K, Iida M, Kiyohara Y (2008) High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese: the Hisayama Study. Arterioscler Thromb Vasc Biol 28:1385–1391CrossRefPubMed
29.
Momiyama Y, Kawaguchi A, Kajiwara I, Ohmori R, Okada K, Saito I, Konishi M, Nakamura M, Sato S, Kokubo Y, Mannami T, Adachi H, Kario K, Iso H, Ohsuzu F, Tsushima M (2009) Prognostic value of plasma high-sensitivity C-reactive protein levels in Japanese patients with stable coronary artery disease: the Japan NCVC-collaborative inflammation cohort study. Atherosclerosis 207:272–276CrossRefPubMed
30.
31.
Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, Anker SD, Atherton J, Böhm M, Butler J, Drazner MH, Michael Felker G, Filippatos G, Fiuzat M, Fonarow GC, Gomez-Mesa JE, Heidenreich P, Imamura T, Jankowska EA, Januzzi J, Khazanie P, Kinugawa K, Lam CSP, Matsue Y, Metra M, Ohtani T, Francesco Piepoli M, Ponikowski P, Rosano GMC, Sakata Y, Seferović P, Starling RC, Teerlink JR, Vardeny O, Yamamoto K, Yancy C, Zhang J, Zieroth S (2021) Universal definition and classification of heart failure: a report of the heart failure society of America, heart failure association of the European society of cardiology, Japanese heart failure society and writing committee of the universal definition of heart failure. Eur J Heart Fail 23:352–380CrossRefPubMed
32.
Lavoie JR, Ormiston ML, Perez-Iratxeta C, Courtman DW, Jiang B, Ferrer E, Caruso P, Southwood M, Foster WS, Morrell NW, Stewart DJ (2014) Proteomic analysis implicates translationally controlled tumor protein as a novel mediator of occlusive vascular remodeling in pulmonary arterial hypertension. Circulation 129:2125–2135CrossRefPubMed
33.
34.
Kashiwakura JC, Ando T, Matsumoto K, Kimura M, Kitaura J, Matho MH, Zajonc DM, Ozeki T, Ra C, MacDonald SM, Siraganian RP, Broide DH, Kawakami Y, Kawakami T (2012) Histamine-releasing factor has a proinflammatory role in mouse models of asthma and allergy. J Clin Invest 122:218–228CrossRefPubMed
35.
Diraison F, Hayward K, Sanders KL, Brozzi F, Laju S, Hancock J, Regazzi R, Molnár E, Váradi A (2011) Translationally controlled tumour protein (TCTP) is a nove glucose-regulated protein that is important for survival of pancreatic beta cells. Diabetologia 54:368–379CrossRefPubMed
36.
Jeon Y, Choi JY, Jang EH, Seong JK, Lee K (2021) Overexpression of translationally controlled tumor protein ameliorates metabolic imbalance and increases energy expenditure in mice. Int J Obes (Lond) 45:1576–1587CrossRefPubMed
37.
Tsai MJ, Yang-Yen HF, Chiang MK, Wang MJ, Wu SS, Chen SH (2014) TCTP is essential for beta-cell proliferation and mass expansion during development and beta-cell adaptation in response to insulin resistance. Endocrinology 155:392–404CrossRefPubMed
Metadata
Title
High plasma levels of fortilin are associated with cardiovascular events in patients undergoing coronary angiography
Authors
Masayuki Aoyama
Yoshimi Kishimoto
Emi Saita
Reiko Ohmori
Masato Nakamura
Kazuo Kondo
Yukihiko Momiyama
Publication date
28-09-2024
Publisher
Springer Japan
Published in
Heart and Vessels
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-024-02465-8

Keynote webinar | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

Keynote webinar | Spotlight on medication adherence

  • Webinar | 27-06-2024 | 18:00 (CEST)

Medication non-adherence is a major barrier to effective healthcare delivery; half of all patients do not follow their doctor’s recommendations or treatment plan.

Our experts explain the fundamentals with a practical discussion of how to manage non-adherence in two common scenarios: hypertension and asthma control.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Watch now
Image Credits